Zhichao Si
Marketing and Medical affairs head at InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428) - Beijing, Beijing, CN
Zhichao Si's Colleagues at InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428)
Zhichao Si's Contact Details
(609) 524-0673
New York, New York
InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428)
Zhichao Si's Company Details
InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428)
Beijing, Beijing, CN • 500 - 999 EmployeesBioTech/Drugs
InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have over 1000 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). And on Sept. 21, 2023, InnoCare successfully got listed on STAR Board of Shanghai Stock Exchange (code: 688428). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.